Express News | HC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals
Oramed Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/20/2024 — HC Wainwright & Co. Reiterates → Neutral 05/17/2023 -12.28% Canaccord Genuity $3 → $2 Mainta
Express News | Compugen Appoints David Silberman As Its New CFO Effective August 15, 2024, Taking Over From Alberto Sessa Who Will Depart On The Same Day
Oramed Pharmaceuticals Seeks New CFO After Resignation
Express News | Oramed Pharmaceuticals Inc - on May 10, David Silberman, Co's CFO Resigned From His Positions With Company
Oramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (Vs US$0.085 Loss in 1Q 2023)
Oramed Pharmaceuticals | 10-Q: Quarterly report
Express News | Oramed Pharmaceuticals Inc - on May 2, Received Additional Payment of About $9.6 Mln Pursuant to Terms of Note
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More
Oramed Pharmaceuticals Welcomes New Audit Committee Chair
Oramed Pharmaceuticals Updates Stock Sale Strategies and Partners
Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Oramed Plans New US Trial for Oral Insulin After Setback, Partners With HTIT to Commercialize Products
Oramed Pharmaceuticals CEO Updates Shareholders on Strategy
MQ, ORMP and EXAI Are Among Pre Market Gainers
Top 4 Health Care Stocks That May Crash This Quarter
As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator
Express News | Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related Assets
Express News | Oramed Pharmaceuticals Said On Jan 22, Co And Unit Entered Into Joint Venture Agreement With Hefei Tianhui Biotech And Technowl; Oramed And HTIT Will Initially Hold Equal Shares In JV, With Each Owning 50% Of Equity
PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization
PhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 ...
OKTA, AMWL and ORMP Among Pre-market Losers